The rapid uptake of Gilead Sciences Inc.’s hepatitis C virus therapy Harvoni while prescriptions of the company’s earlier HCV blockbuster Sovaldi hold steady suggests that Harvoni has expanded the treatment pool for HCV, according to a report from the CVS Health Research Institute.
The report notes that although the prescribing rate for Harvoni (sofosbuvir/ledipasvir) surpassed Sovaldi (sofosbuvir) by the end of November, “in...